Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is set to announce third quarter earning results on Monday 2nd November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, SNDX to report 3Q20 loss of $ 0.44 per share.
For the full year, analysts anticipate top line of $ 1.50 million, while looking forward to loss of $ 1.8 per share bottom line.
Stock Performance
On Friday, shares of Syndax Pharmaceuticals, Inc. has traded high as $ 18.25 and has cracked $ 17.08 on the downward trend, reaching $ 17.41 with volume of 429.90 thousand shares.
According to the previous trading day, closing price of $ 17.41, representing a 237.20 % increase from the 52 week low of $ 5.35 and a 17.89 % decrease over the 52 week high of $ 21.97.
The company has a market capital of $ 671.14 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Syndax Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.syndax.com
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The companys lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer.
